NRX PHARMACEUTICALS INC (NRXP) Stock Price, Quote, News and Overview
NASDAQ:NRXP - Nasdaq - US6294442099 - Common Stock - Currency: USD
NRXP Quote, Performance and Key Statistics
NASDAQ:NRXP (4/28/2025, 8:00:02 PM)
2.1
+0.03 (+1.45%)
The current stock price of NRXP is 2.1 USD. In the past month the price increased by 3.45%.
NRXP Competitors/Peers
Symbol | Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| LLY | ELI LILLY & CO | 67.48 | 831.66B | ||
| JNJ | JOHNSON & JOHNSON | 15.46 | 374.37B | ||
| NVO | NOVO-NORDISK A/S-SPONS ADR | 18.15 | 277.97B | ||
| NVS | NOVARTIS AG-SPONSORED ADR | 14.19 | 222.45B | ||
| AZN | ASTRAZENECA PLC-SPONS ADR | 16.85 | 216.81B | ||
| MRK | MERCK & CO. INC. | 10.68 | 209.34B | ||
| PFE | PFIZER INC | 7.41 | 130.73B | ||
| SNY | SANOFI-ADR | 13.7 | 129.16B | ||
| BMY | BRISTOL-MYERS SQUIBB CO | 6.6 | 98.60B | ||
| GSK | GSK PLC-SPON ADR | 8.75 | 77.12B | ||
| ZTS | ZOETIS INC | 25.94 | 68.50B | ||
| TAK | TAKEDA PHARMACEUTIC-SP ADR | 32.96 | 47.71B |
Related stock screener links
About NRXP
Company Profile
NRX Pharmaceuticals, Inc. is a clinical-stage small molecule pharmaceutical company. The company is headquartered in Wilmington, Delaware. The company went IPO on 2017-11-20. The firm is developing therapeutics based on its N-methyl-D-aspartate (NMDA) platform for the treatment of central nervous system disorders, specifically suicidal bipolar depression, chronic pain, and post-traumatic stress disorder (PTSD). The firm has two lead compounds, NRX-100, a proprietary presentation of ketamine and NRX-101, a fixed-dose combination of D-cycloserine (DCS) and lurasidone. The firm is developing NRX-101, a Food and Drug Administration (FDA)-designated investigational therapy for suicidal treatment-resistant bipolar depression and chronic pain. NRX-101 is a combined NMDA/5-HT2A-targeted medicine designed to address both depression and suicidal ideation, consisting of an oral, fixed dose combination of DCS and lurasidone. Its NRX-100 is racemic ketamine, which is a generic anesthetic.
Company Info
NRX PHARMACEUTICALS INC
1201 Orange Street, Suite 600
Wilmington DELAWARE US
CEO: Richard Ackerman
Employees: 2
Company Website: https://www.nrxpharma.com/
Investor Relations: https://ir.nrxpharma.com/
Phone: 14842546134
NRX PHARMACEUTICALS INC / NRXP FAQ
What is the stock price of NRX PHARMACEUTICALS INC today?
The current stock price of NRXP is 2.1 USD. The price increased by 1.45% in the last trading session.
What is the ticker symbol for NRX PHARMACEUTICALS INC stock?
The exchange symbol of NRX PHARMACEUTICALS INC is NRXP and it is listed on the Nasdaq exchange.
On which exchange is NRXP stock listed?
NRXP stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for NRX PHARMACEUTICALS INC stock?
9 analysts have analysed NRXP and the average price target is 28.82 USD. This implies a price increase of 1272.14% is expected in the next year compared to the current price of 2.1. Check the NRX PHARMACEUTICALS INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is NRX PHARMACEUTICALS INC worth?
NRX PHARMACEUTICALS INC (NRXP) has a market capitalization of 35.53M USD. This makes NRXP a Nano Cap stock.
How many employees does NRX PHARMACEUTICALS INC have?
NRX PHARMACEUTICALS INC (NRXP) currently has 2 employees.
What are the support and resistance levels for NRX PHARMACEUTICALS INC (NRXP) stock?
NRX PHARMACEUTICALS INC (NRXP) has a support level at 1.99 and a resistance level at 2.11. Check the full technical report for a detailed analysis of NRXP support and resistance levels.
Should I buy NRX PHARMACEUTICALS INC (NRXP) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of NRXP, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of NRXP, evaluating the profitability, health, valuation and growth aspects
- NRX PHARMACEUTICALS INC (NRXP) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- NRX PHARMACEUTICALS INC (NRXP) Sales and EPS estimates to see what analysts future expectations are.
- NRX PHARMACEUTICALS INC (NRXP) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- NRX PHARMACEUTICALS INC (NRXP) Insider and Institutional Ownership to learn about the owners and their transactions.
- NRX PHARMACEUTICALS INC (NRXP) Stock Chart to make your own analysis
- NRX PHARMACEUTICALS INC (NRXP) Latest news and press-releases to stay up to date.
Does NRX PHARMACEUTICALS INC (NRXP) stock pay dividends?
NRXP does not pay a dividend.
When does NRX PHARMACEUTICALS INC (NRXP) report earnings?
NRX PHARMACEUTICALS INC (NRXP) will report earnings on 2025-05-12.
What is the Price/Earnings (PE) ratio of NRX PHARMACEUTICALS INC (NRXP)?
NRX PHARMACEUTICALS INC (NRXP) does not have a PE ratio as the earnings reported over the last twelve months were negative (-2.31).
What is the Short Interest ratio of NRX PHARMACEUTICALS INC (NRXP) stock?
The outstanding short interest for NRX PHARMACEUTICALS INC (NRXP) is 9.28% of its float. Check the ownership tab for more information on the NRXP short interest.
NRXP Technical Analysis
ChartMill assigns a technical rating of 1 / 10 to NRXP. When comparing the yearly performance of all stocks, NRXP is a bad performer in the overall market: 73.12% of all stocks are doing better.
NRXP Financial Highlights
Over the last trailing twelve months NRXP reported a non-GAAP Earnings per Share(EPS) of -2.31. The EPS increased by 42.25% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -688.2% | ||
| ROE | N/A | ||
| Debt/Equity | N/A |
NRXP Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 82% to NRXP. The Buy consensus is the average rating of analysts ratings from 9 analysts.